Omeprazole
Omeprazole is a proton pump inhibitor (PPI) that acts as an antagonist at H+/K+ ATPases and is clinically used to treat gastroesophageal reflux disease (GERD), dyspepsia, and peptic ulcer disease. Omeprazole exhibits antacid, anti-ulcerative, and anti-diabetic activities; it also inhibits the mitochondrial carnitine/acylcarnitine transporter. Omeprazole decreases blood glucose levels and Hb1Ac, improves glucose tolerance, and induces β cell neogenesis and activation.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18951002
| Cas No. |
73590-58-6 |
|---|---|
| Purity |
≥98% |
| Formula |
C17H19N3O3S |
| Formula Wt. |
345.42 |
| Chemical Name |
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole |
| IUPAC Name |
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole |
| Synonym |
Antra; Gastrogard; Losec; Mepral; Omepral; Parizac Prilosec; Zoltum |
| Melting Point |
156°C |
| Solubility |
Soluble in ethanol or methanol. Slightly soluble in acetone, isopropanol, or water. |
| Appearance |
White Crystalline powder |
Tonazzi A, Eberini I, Indiveri C. Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. PLoS One. 2013 Dec 9;8(12):e82286. PMID: 24349247.
Ward RM, Kearns GL. Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013 Apr;15(2):119-31. PMID: 23512128.
Mefford IN, Mefford JT, Burris CA. Improved diabetes control and pancreatic function in a type 2 diabetic after omeprazole administration. Case Rep Endocrinol. 2012;2012:468609. PMID: 22937295.
